Clinical Trials on Breast; Atrophy in Austria

Total 743 results

National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Kirilys Therapeutics Inc.

Active, not recruiting

Study of ASN004 in Patients With Advanced Solid Tumors (ASN004)

Solid Tumor

United States
University of Michigan
Medical University of South Carolina; Emory University; Medical College of Wisconsin and other collaborators

Completed

Genetic Determinants of Congenital Heart Disease Outcomes (GECHO)

Congenital Heart Disease | Hypoplastic Left Heart Syndrome | Hypoplastic Right Heart Syndrome | d-Transposition of the Great Arteries

United States, Australia
Greenwich LifeSciences, Inc.

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)

Breast Cancer

France, United States, Spain, Germany, Italy, Poland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Percheron Therapeutics

Recruiting

A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Turkey, United Kingdom, Australia, Serbia, Bulgaria
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Fusion Pharmaceuticals Inc.

Terminated

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein Overexpression

United States, Australia
Cooperative International Neuromuscular Research...

Completed

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States, Canada, Argentina, Australia, Israel, Italy
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) (LELANTOS-1)

Duchenne Muscular Dystrophy

United States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
Syros Pharmaceuticals

Terminated

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Advanced Solid Tumors

United States, Canada, France
ReveraGen BioPharma, Inc.
University of Pittsburgh; Cooperative International Neuromuscular Research...

Completed

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
FibroGen

Active, not recruiting

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

Duchenne Muscular Dystrophy

United States, Spain, Canada, Australia, China, Italy, Belgium, France, Netherlands, Austria, United Kingdom
Santhera Pharmaceuticals

Completed

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (DELOS)

Muscular Dystrophy, Duchenne | Ambulatory Care

United States, Spain, Austria, Belgium, France, Germany, Italy, Netherlands, Sweden, Switzerland
Pfizer

Completed

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Hepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditions

United States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
Haihe Biopharma Co., Ltd.

Terminated

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Solid Tumor | Prostate Cancer | Endometrial Cancer

United States, Australia, China
Cooperative International Neuromuscular Research...
aTyr Pharma, Inc.; Muscular Dystrophy Canada; FSHD Global Research Foundation; FSH...

Completed

A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Canada, Australia, Sweden, United Kingdom
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Murdoch Childrens Research Institute

Completed

Nitric Oxide During Bypass for Arterial Switch Operation (NASO)

Transposition of Great Vessels | Low Cardiac Output Syndrome

Malaysia, Australia, Canada, Indonesia
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Novartis Pharmaceuticals

Completed

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Renal Cancer | Hepatocellular Cancer

Taiwan, Germany, Italy, Austria, Switzerland, Hong Kong, Japan, Canada, United States
Corvus Pharmaceuticals, Inc.

Completed

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Renal Cell Cancer | Non-hodgkin Lymphoma | Metastatic Castration Resistant Prostate...

United States, Australia
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Janssen Research & Development, LLC

Completed

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
AMO Pharma Limited

Recruiting

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy (REACH CDM X)

Congenital Myotonic Dystrophy

United States, Canada, Australia, New Zealand
Santhera Pharmaceuticals

Terminated

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) (SIDEROS-E)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Austria, France, Germany, Italy, Spain, Switzerland
AMO Pharma Limited

Completed

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Congenital Myotonic Dystrophy

United States, Canada, New Zealand, Australia, United Kingdom
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
NSABP Foundation Inc
National Cancer Institute (NCI); Southwest Oncology Group; North Central Cancer... and other collaborators

Completed

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Breast Cancer

United States, Canada, Puerto Rico
Seagen Inc.

Terminated

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Cervical Cancer | Ovarian Cancer | Peripheral T-cell Lymphoma | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Classical Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | Cutaneous Melanoma | Gastroesophageal Junction...

United States, Spain, Canada, United Kingdom, France, Italy
University of Sydney
Austin Health; Peter MacCallum Cancer Centre, Australia; Western Sydney Local... and other collaborators

Not yet recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology (LEARN)

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Arrhythmias, Cardiac | Pancreatic Cancer | Brain Cancer | Liver Cancer | Prostatic Cancer | Spinal Neoplasm

Australia
UMC Utrecht
M.D. Anderson Cancer Center; Odense University Hospital; Radboud University Medical... and other collaborators

Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM)

Neoplasms | Quality of Life | Breast Cancer | Head and Neck Cancer | Head and Neck Neoplasms | Gynecologic Cancer | Liver Neoplasms | Pancreatic Neoplasms | Pancreatic Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Rectal Neoplasms | Prostate Cancer | Brain Cancer | Brain Tumor | Bladder Cancer | Liver Metastases | T... and other conditions

United States, Netherlands, Germany, Canada, Denmark, United Kingdom, Australia, Belgium, Italy
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

HER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid Tumor

China, Australia, United States
Pfizer

Active, not recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Spain, Belgium, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, France, Italy, United Kingdom, Russian Federation, Israel, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

Switzerland, Germany, Austria
Edgewise Therapeutics, Inc.
Medpace, Inc.; SYSNAV; ImagingNMD

Recruiting

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Becker Muscular Dystrophy

United States, Netherlands, United Kingdom
PTC Therapeutics

Completed

Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Dystrophinopathy

United Kingdom, Canada, Germany, Spain, Sweden, Italy, Australia, Belgium, France, Israel
Catabasis Pharmaceuticals

Terminated

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)

Duchenne Muscular Dystrophy

United States, Canada, Australia, United Kingdom, Germany, Sweden
Sarepta Therapeutics, Inc.

Active, not recruiting

Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (MOMENTUM)

Duchenne Muscular Dystrophy

United States, Belgium, Spain, United Kingdom, Netherlands, Germany, Canada, Italy
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
PTC Therapeutics
Cooperative International Neuromuscular Research Group; The John Walton Muscular...

Active, not recruiting

Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Muscular Dystrophy, Duchenne

Germany, France, United Kingdom, Brazil, Italy, Austria, Sweden, Czechia, Greece, Hungary, Israel, Latvia, Norway, Portugal, Romania, Slovenia
Xoft, Inc.
Icad, Inc.

Active, not recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Ductal Carcinoma in Situ | Invasive Ductal Carcinoma

United States, Portugal, Australia
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

United States, Spain, Korea, Republic of, Taiwan, Italy, Australia, France
Cooperative International Neuromuscular Research...
United States Department of Defense; National Institutes of Health (NIH); U.S... and other collaborators

Unknown

Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, Australia, India, Israel, Argentina, Italy, Sweden
AstraZeneca
Daiichi Sankyo Co., Ltd.

Recruiting

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Canada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands

Clinical Trials on Breast; Atrophy in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations